Clinical and pharmacologic characteristic of Angiotensin II Receptor Blockers in the treatment of arterial hypertension and chronic heart failure
https://doi.org/10.51523/2708-6011.2009-6-3-1
Abstract
A survey is presented of the angiotensin II receptor antagonists (AT1 blockers, sartans) and their general properties and similarities. Accordingly, their receptor profile, pharmacokinetic and therapeutic applications are discussed. In addition, attention is paid to the individual characteristics of the AT1 blockers now available.
About the Authors
G. M. Bronskaya
Gomel State Medical University
Belarus
Belarus
T. A. Korshak
Grodno State Medical University
Belarus
Belarus
D. V. Kazakevich
Grodno State Medical University
Belarus
Belarus
References
1. Angiotensin receptors and their antagonists / T.L. Goodfriend [et al.] // N Engl J Med. - 1996. - Vol. 334. - P. 1649-1654.
2. Tarascon Pocket Pharmacopoeia. - Loma Linda, 2006. - P. 86.
3. Остроумова, О. Д. Антагонисты рецепторов ангиотензина II / В. Г. Кукес [и др.] // Клиническая фармакология: учеб. / В. Г. Кукес. - 3-е изд., испр. и доп. - М., 2004. - С. 297-300.
4. Moser, M. Clinical Management of Hypertension / M. Moser. - 2nd ed. - PCI, 997. - 192 р.
5. The Seventh Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure // JAMA. - 2003. - Vol. 289. - P. 2560-2571.
6. Morrison, A. E. Hypertension / A. E. Morrison // The Washington Manual™ of Medical Therapeutics / G. B. Green [et al.]. - 31st ed. - Lippincott Williams & Wilkins, 2004. - P. 72-92.
7. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against Atenolol / B. Dahlof [et al.] // Lancet. - 2002. - Vol. 359. - P. 995-1003.
8. RENAAL-study investigations. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy / B. M. Brenner [et al.] // N Engl J Med. - 2001. - Vol. - 345. - P. 861-869.
9. Pitt, B. On behalf of the ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly Study, ELITE) / B. Pitt [et al] // Lancet. - 1997. - Vol.349. - P. 747-752.
10. Burnier, M. Angiotensin II type 1 receptor blockers / M. Burnier // Circulation. - 2001. - Vol. 103. - P. 904-912.
11. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double blind intervention trial / H. Lithell [et al.]// J Hypertens. - 2003. - Vol. 21. - P. 875-886.
12. White, H. D. Candesartan and heart failure: the allure of CHARM / H. D. White //Lancet. - 2003. - Vol. 362. - P. 754-755.
13. McCellan, K. J. Eprosartan / R. J. McCellan, J. A. Balfour // Drugs. - 1998. - Vol. 55. - P. 713-718.
14. Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes / E. J. Lewis [et al.] // N EnglJ Med. - 2001. - Vol. 345. - P. 851-860.
15. Gillis, J. C. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension / J. C. Gillis, A. Markham // Drugs. - 1997. - Vol. 54. - P. 885-902.
16. Brunner, H. R. Clinical efficacy of olmesartan medoxomil / H. R. Brunner, P. Laers // J Hypertens. - 2003. - Vol. 21 (Suppl 2). - P. 543-546.
17. Unger, T. The role of olmesartan medoxomil in the management of hypertension / T. Unger [et al.] // Drugs. - 2004. - Vol. 64. - P. 2731-2739.
18. Angiotensin receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy / A. H. Barnett [et al.] // N Engl J Med. - 2004. - Vol. 351. - P. 1952-1961.
19. Angiotensin type I receptor include peroxizome proliferator activated receptoryactivity / M. Schupp [et al.] // Circulation. - 2004. - Vol. 109. - P. 2054-2057.
20. Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan / S. G. Chrysants [et al.] // J Hum Hypertens. - 2005. - Vol. 19. - P. 173-183.
21. VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimes based on valsartan or amlodipine: the VALUE randomized trial S. Julius [et al.] // Lancet. - 2004. - Vol. 363. - P. 2022-2031.
22. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both / M. A. Pfeffer [et al.] // N Engl J Med. - 2003. - Vol. 349. - P. 1893-1906.
23. Viberti, G.C. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure independent effect / G. C. Viberti, M. N. Wheeldon // Circulation. - 2002. - Vol. 106. - P. 672-678.
Review
For citations:
Bronskaya G.M., Korshak T.A., Kazakevich D.V. Clinical and pharmacologic characteristic of Angiotensin II Receptor Blockers in the treatment of arterial hypertension and chronic heart failure. Health and Ecology Issues. 2009;(3):7-11. (In Russ.) https://doi.org/10.51523/2708-6011.2009-6-3-1
Views: 364
Email this article 